Innovative Minds in Health Spain's 2024 Trailblazing Leaders

1. June | Issue 01 | 2024 Innovative Minds in Health: Spain's 2024 Trailblazing Leaders The Role of Innova?ve Leaders in Transforming Healthcare in Spain Effec?ve Communica?on Strategies for Healthcare Leaders in Spain Philippe Clavel CEO Curapath Philippe Clavel Diversified Expertise & Experience Shaping the Pharmaceutical Industry with

4. Editor’s Note

5. Shaping the Future of Global Healthcare T he critical field of healthcare is progressing at an alarming rate. This progress is driven by significant inventions from immunotherapy to telehealth which were possible because of some of the brilliant minds in healthcare. Spain, a country rich in history and culture, has emerged as a cradle of healthcare innovation, nurturing some of the most extraordinary talents in the field. their respective fields but have also paved the way for future innovations. As you delve into their journeys, you’ll find more than just success stories. You’ll uncover tales of perseverance, creativity, and relentless dedication to improving human health. These narratives are designed not only to inspire but also to enlighten, offering valuable insights into the future of healthcare. They serve as evidence to the power of innovation and the impact that passionate individuals can have on global health. At Euro Health Leaders, we’re committed to showcasing such inspiring individuals who drive progress in the industry. Our latest edition, ‘Innovative Minds in Health: Spain’s 2024 Trailblazing Leaders,’ is a tribute to the visionaries who are redefining healthcare. Turn the page and embark on a journey through the minds of Spain’s most innovative healthcare leaders. Within these pages, you’ll discover the resilient stories of pioneers whose work spans the entire spectrum of healthcare - from cutting-edge pharmaceuticals to novel psychotherapy techniques. These leaders have not only made impressive contributions to Natalie May Natalie May - Natalie May

6. 08 Philippe Clavel Shaping the Pharmaceutical Industry with Diversified Expertise & Experience Cover Story

7. Profiles 20 Carlos Rubio Terrés Pioneering Strategic Healthcare Solutions 28 Dr. Mario Scheib Leading the Future of Psychiatry with Innovative, Intensive Therapies 36 Marta Moya Martín Sparking a Beauty Revolution with Passion and Vision Articles 24 Effective Communication Strategies for Healthcare Leaders in Spain 32 The Role of Innovative Leaders in Transforming Healthcare in Spain

8. L E A D E R S EUR Health Editor-in-Chief Thanh Truong Managing Editor Pearl Shaw Executive Editor Natalie May Visualiser David King Art & Design Head Samuel Martinez Co-designer Paul Belin Art & Picture Editor Grace Brown Business Development Manager Emily Jones Business Development Executives Anna Smith, Jack Miller Marketing Manager Bill Thompson Sales Executives Mike, Carl, Sandra Technical Consultants David, Robert Assistant Technical Head Joseph Taylor Technical Head Jacob Smile Assistant Digital Marketing Manager Daniel Jones Digital Marketing Manager Alina Sege SME-SMO Executive Gemson Research Analyst Eric Smith Circulation Manager James Carter sales@eurohealthleaders.com June, 2024 Contact Us: Insights Success Media and Technology Pvt. Ltd. Survey No.133/134, Brand Square, Office No. 512, Kunjir Chowk, Pimple Saudagar, Pune, Maharashtra 411027. Phone - India: 7410033802, 8956487823 Email: info@eurohealthleaders.com For Subscription: www.eurohealthleaders.com https://twitter.com/eurohealthleaders Insights Success Media Tech LLC 555 Metro Place North, Suite 100, Dublin, OH 43017, United States Phone - +1614-602-4132 Email: info@eurohealthleaders.com For Subscription: www.eurohealthleaders.com Follow us on : www.facebook.com/eurohealthleaders/ We are also available on : Copyright © 2024 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights success. Reprint rights remain solely with Insights Success Media and Technology Pvt. Ltd. Euro Health Leaders is powered by Insights Success Media and Technology Pvt. Ltd.

9. INNOVATIVE MINDS IN HEALTH: SPAIN'S 2024 TRAILBLAZING LEADERS Featuring Person Company Brief Strength and Conditioning Education strengthandconditionin geducation.com Brendan Chaplin is a high-performance coach and entrepreneur who focuses on mentoring other coaches to achieve their version of success. Brendan Chaplin Chairman & Founder Carlos Rubio Terrés is a healthcare industry expert who specializes in providing strategic guidance and data-driven solutions to address the evolving challenges in the healthcare arena. Health Value healthvalue.org Carlos Rubio Terrés Director Dr. Mario Scheib is a leading specialist in psychosomatic medicine and psychotherapy, pioneering the use of innovative treatments like ketamine-assisted psychotherapy and brain stimulation. Dr. Mario Scheib Specialist for Psychosomatic Medicine and Psychotherapy Instituto Dr. Scheib Mallorca psychosomatik.com Marta Moya Martín is a visionary entrepreneur who has transformed her diverse background in finance and fashion into a successful career in the beauty and wellness industry. MIA COSMETICS PARIS miacosmeticsparis.com Marta Moya Martín Co-founder & COO Philippe Clavel is a seasoned healthcare leader with a 27-year career in the Chemical & Pharmaceutical Industry, known for his strategic insight, customer- centricity, and ability to drive positive change. Curapath curapath.com Philippe Clavel CEO

10. COVER STORY Philippe Clavel Shaping the Pharmaceutical Industry with Diversified Expertise & Experience Philippe advocates for a management style rooted in trust, empowerment, and authenticity.

11. Philippe Clavel CEO Curapath

12. S uccessful healthcare leaders possess more than just knowledge and expertise. They embrace an open- minded attitude and a readiness to adapt to diverse environments. These essential attributes are crucial in navigating varied cultural landscapes. Philippe Clavel exemplifies these qualities flawlessly, positioned to drive positive change within the healthcare sector. Boasting a remarkable 27-year career in the Chemical & Pharmaceutical Industry, Philippe is a versatile leader with a deep understanding of both science and customer- centricity. Renowned for his strategic insight and his talent for guiding and motivating others, he currently holds the position of CEO at Curapath. leading the way in the development, manufacturing, and formulation of lipid- and polymer-based nanoparticles for state-of-the-art therapeutic delivery technologies. This innovative company is Before his tenure at Curapath, Philippe had the privilege of working for three prominent industrial companies in the pharmaceutical sector: Rhodia (now part of Solvay/Syensqo), Sanofi, and Seqens. He credits his former colleagues, managers, and teams for the wealth of knowledge he gained through diverse projects spanning R&D, manufacturing, process development, business development, and sales. Philippe’s scientific background, including an engineering diploma and a PhD in organic chemistry, laid the foundation for his career. Initially focused on chemical route scouting, process development, and industrial launches, Philippe’s turning point came in 2007 when he was tasked with creating the API CDMO activity at Sanofi. This experience led him to the world of business, where he successfully built a thriving €50+ million revenue- generating unit from scratch within six years. Throughout his career, Philippe has embraced opportunities for personal and professional growth, leveraging exchanges and encounters across various countries and cultures. His experiences in Europe, US, China, India, and Japan have provided invaluable insights into global business dynamics and the importance of relationship-building in diverse contexts. Japan, in particular, has been a transformative experience for Philippe, teaching him the value of patience and the significance of nurturing long-lasting partnerships before pursuing business objectives. Philippe leads Curapath through a significant transition, from supporting discovery and R&D projects to focusing on

13. Innovative Minds in Health: Spain's 2024 Trailblazing Leaders His vision is to position Curapath as the go-to CDMO for non-viral gene therapy approaches, solidifying its reputation as a one-stop shop in the industry.

15. late-stage development and GMP manufacturing. Leveraging the company’s scientific expertise and agility, he is heading its next wave of growth with enthusiasm and determination. Philippe’s story serves as a source of inspiration for numerous aspiring healthcare professionals. Anticipating Needs and Prioritizing Client Relationships Philippe has 15 years of experience in the business particularly in the field of Contract Development and Manufacturing Organization (CDMO). His journey has taught him that successful CDMOs prioritize customer intimacy and reliability. Establishing a close relationship with clients allows for anticipating their needs and decision- making criteria, enabling access to valuable projects. Once purchase orders are received, timely delivery of the right quality and quantity is paramount for customer satisfaction and building a positive reputation. Operational excellence is the cornerstone of success in the CDMO industry, as reliability serves as the most effective business amplifier. At Curapath, Philippe aims to prioritize customer-centricity and operational excellence, placing them at the heart of the company’s activities. Additionally, he advocates for a collaborative approach to driving business and forming partnerships. Drawing from past experiences, Philippe understands the importance of fair and balanced contracts. While maximizing value for his company, he recognizes the necessity of flexibility when customers encounter challenges, preventing potential bankruptcy situations. Philippe believes that contracts skewed in favor of one party often lead to disputes, lack of transparency, and diminished value creation for patients. Thus, he champions win/win solutions and promotes a mindset of fairness and cooperation throughout Curapath. Prioritizing Patient Well-Being Under Philippe’s leadership, Curapath is guided by a clear sense of purpose: ‘Leading next-generation non-viral gene delivery to improve life.’ This vision is anchored in three core values that shape the company’s direction and operations: • Caring: At Curapath, caring extends beyond mere business transactions. The company prioritizes the well-being of team members, suppliers, customers, and patients.

16. • Resilience: Resilience is ingrained in Curapath’s DNA. The team approaches challenges with determination and creativity, never backing down in the face of adversity. Instead, they embrace innovation, thinking outside the box to design, test, and improve solutions continuously. Solving: At Curapath, problems are viewed as opportunities for innovation and growth. In facing adversity, Philippe advocates for a collective approach to problem- solving, where diversity of thought and perspective are embraced. • These core values are integral to how Curapath operates and interacts with others. Excellence in Every Aspect of Operations As CEO, Philippe prioritizes strategic initiatives aimed at ensuring that Curapath remains at the forefront of innovation and excellence in healthcare services. Since the beginning of 2024, several key initiatives have been reinforced: • Customer Centricity: Placing customers and partners at the heart of all activities is paramount for Curapath. The company simplifies its organizations and processes to enhance customer experience, ensuring transparent and timely communication at all stages of engagement. By fostering proactiveness rather than reactiveness, Curapath aims to exceed customer expectations and strengthen relationships with its partners. Operational Excellence: Curapath implements an Operational Excellence plan to optimize ways of working and procedures across the organization. This involves fostering a culture of continuous improvement, where employees are encouraged to • Intellectual Property (IP) Protection: Recognizing the significance of IP as one of the company’s key assets, Curapath prioritizes its protection. This involves implementing robust measures to safeguard intellectual property rights and highlight the company’s capabilities effectively in the market. Additionally, Curapath will launch an Innovation Committee to align business trends with R&D investment, ensuring that the company remains a leader in its segments and generates additional IP through innovative approaches. •

17. identify and implement efficiency-enhancing measures. The company strikes the right balance between performance and robustness, ensuring that operational excellence is ingrained in every aspect of its operations. drug delivery systems. These systems are tailored to support a diverse array of applications including cell therapy, gene therapy, and vaccine delivery, underscoring Curapath’s commitment to advancing healthcare solutions. By prioritizing these strategic initiatives, Philippe ensures that Curapath remains agile, innovative, and customer- focused, thus reinforcing its position as a leader in healthcare services. For over a decade, Curapath has been instrumental in supporting drug innovators by providing expertise in stealth shielding polymers (polyaminoacids), functional polymer & lipid excipients, linkers for bioconjugation, and API polymers used for therapeutics. Its agile teams boast exceptional scientific proficiency and project management capabilities, seamlessly guiding projects from discovery through to commercial launch while ensuring the timely achievement of milestones. The Foundation of Curapath’s Offerings Curapath stands as a premier CDMO specializing in pioneering novel drug delivery systems (DDS), distinguishing itself as a leader in the nanocarrier segment within the pharmaceutical industry. With an extensive portfolio encompassing research and development services alongside manufacturing capabilities, Curapath offers a comprehensive suite of solutions ranging from polymeric and lipidic excipients to encapsulation, lipid nanoparticle (LNP) formulation, and fill & finish services. Curapath prides itself on its collaborative approach, acting as an extension of its customers’ teams and offering flexibility with tailor-made scopes of work. The company excels in fast-tracking projects under tight time constraints and employs innovative approaches for effective problem- solving. Additionally, Curapath offers proprietary excipients that have the potential to revolutionize nanoparticle formulations, enabling the attainment of the desired product target profile. At the core of Curapath’s offerings lies unmatched technical support and analytical expertise, facilitating the custom design, development, and end-to-end Good Manufacturing Practice (GMP) manufacturing of polymer and lipid-based

18. Authenticity and Proximity a blend of people and cultures. Moreover, he highlights the importance of reconciling personal and global interests, recognizing that everyone has a role to play in building a sustainable future for the planet and the company. Philippe advocates for a management style rooted in trust, empowerment, and authenticity. He believes that when leaders resort to fear tactics, teams become stagnant and disengaged, leading to suboptimal outcomes or even failure. Instead, Philippe fosters an environment of trust, where teams are empowered to exceed expectations and achieve remarkable results through clear guidance and autonomy. At Curapath, responsibility extends beyond financial success to encompass environmental stewardship and the development of its people. Philippe envisions a growth story for the company that prioritizes both business expansion and the well-being of its employees, while also minimizing its carbon footprint. He emphasizes the significance of taking small steps every day in the right direction, understanding that these incremental actions can yield significant long- term impact. For Philippe, trust is not just a virtue but a strategic investment in people. By providing teams with the freedom to take initiative, analyze situations, and make decisions, he instills a sense of responsibility that drives growth and development. This trust, coupled with a sense of responsibility, fuels engagement and creates value for both the company and its customers. Employee-Centric Handbook Under Philippe’s leadership, the well-being and professional development of Curapath’s teams are fundamental priorities. At the end of 2023, the company collaborated with employees to establish a comprehensive handbook aimed at enhancing employee satisfaction and growth. The handbook encompasses various initiatives, including: Authenticity and closeness to the teams are central to Philippe’s approach. Through direct exchanges and proximity, he encourages open dialogue, challenges ideas, and invites proposals from everyone. While not all suggestions may be implemented, decisions are educated, shared, and understood by the teams, fostering a culture of belonging and ownership. • Health and Safety at Work: Ensuring the health and safety of all employees is paramount, with a primary objective outlined in the handbook. Flexible Working Hours and Remote Work Policy: Curapath recognizes the importance of flexibility in work arrangements, allowing employees to achieve a better work-life balance. English Courses: Investing in employees’ language skills through English courses ensures they are equipped for global communication and collaboration. Social Benefits: The company provides support to employees for transportation, nursery costs, and meals, prioritizing their social well-being. Social Activities and Events: Organizing social activities and events fosters a sense of community and camaraderie among team members. Free Fruit: Offering free fruit on a daily basis promotes healthy eating habits and overall well-being in the workplace. Beginning in 2024, Curapath introduced a complementary health insurance plan for all employees, further demonstrating its commitment to their well- being. Philippe’s management philosophy aligns with Curapath’s core values, particularly the value of “welcoming problems.” This mindset is integral to the company’s identity, as it positions Curapath as a go-to partner for innovative pharmaceutical and biotech companies facing technological challenges. Leveraging the expertise of its teams, Curapath proposes scientific solutions and executes them through development and manufacturing, fulfilling its sense of purpose and creating value for customers and patients. • • • Leveraging Conflicting Ideas for Innovative Solutions • Philippe emphasizes the unprecedented uncertainty, ambiguity, and complexity characterizing today’s world. In such a dynamic environment, agility emerges as a critical skill set for navigating challenges effectively. Amidst these turbulent times, resilience takes precedence as the foremost value. While performance remains essential for profitability, robustness is the pathway to sustainability and resilience. • • In facing adversity, Philippe advocates for a collective approach to problem-solving, where diversity of thought and perspective are embraced. He believes that the best solutions arise from conflicting ideas, diverse opinions, and In addition to these initiatives, Curapath prioritizes continuous learning and development for its teams. Regular training sessions are conducted to enhance expertise in

19. relevant areas, and career paths are created to support progression, including opportunities in project management and business development. In the context of pharmaceutical development, Philippe underscores the significance of drug delivery systems, particularly for nucleic acids like messenger RNAs (mRNAs). The encapsulation of mRNA molecules in lipid nanoparticles has emerged as a critical technique to enhance stability, guide cellular uptake, and optimize therapeutic outcomes. The COVID-19 pandemic has accelerated the development of such drug delivery systems, highlighting their criticality in modern medicine. The establishment of a Continuous Improvement Committee provides a platform for employees to share best practices, drive problem-solving initiatives, and contribute to the company’s overall development. Employee feedback, gathered through annual surveys, informs corporate objectives and action plans, underscoring Curapath’s dedication to continuous improvement and employee satisfaction. Philippe emphasizes Curapath’s pivotal role in the evolving landscape of personalized medicine and gene therapy. With a specific focus on non-viral gene therapy, Curapath is poised to address a wide range of therapeutic areas, including infectious diseases, rare diseases, and oncology. Leveraging its expertise in polymer and lipid excipients, chemical and biological active ingredient conjugation, and GMP manufacturing of lipid nanoparticles, Curapath is well-positioned to meet the growing demand in this sector. Philippe’s approach ensures that Curapath’s teams are not only supported in their professional growth but also nurtured in an environment that prioritizes their well-being and cultivates a culture of continuous improvement. Accelerating Development Philippe, having joined Curapath four months ago, has initiated key actions aimed at strengthening relationships with top customers and forging new strategic partnerships to bolster the company’s market offering. His vision is to position Curapath as the go-to CDMO for non-viral gene therapy approaches, solidifying its reputation as a one-stop shop in the industry. As lipid nanoparticles are extensively utilized for encapsulating RNAs, Curapath offers comprehensive support for companies developing complex formulations based on nanoparticles. With a strong track record in providing strategic guidance and operational excellence across various stages of drug development, Curapath is committed to delivering transformative solutions to patients, exemplifying its dedication to advancing healthcare innovation under Philippe’s leadership. Reflecting on the COVID-19 pandemic, Philippe acknowledges the vital contributions of various players across the pharmaceutical value chain, beyond the well- known vaccine developers. Large corporations like Lonza, Corden Pharma, along with smaller actors like Certest Biotec played crucial roles in enabling mass vaccination efforts and facilitating testing and diagnosis, highlighting the importance of collaboration and innovation specifically in times of crisis.

21. “ The role of a leader in healthcare is to create an environment where people feel empowered to provide the best possible care to patients. - Rana Awdish

22. CARLOS RUBIO TERRÉS Pioneering Strategic Healthcare Solu?ons CARLOS RUBIO TERRÉS Director Health Value, Madrid, Spain June 2024 www.eurohealthleaders.com 20

23. " Innova?ve Minds in Health: Spain's 2024 Trailblazing Leaders T efficacy of medical interventions meets the careful evaluation of economic viability. Amidst this backdrop, emerges HEALTH VALUE a consultancy firm that not only directs through the complexities of the industry but also pioneers innovative approaches to address evolving challenges. he demand for strategic guidance and data-driven solutions has never been more pronounced in today’s growing healthcare arena, where the HEALTH VALUE has its roots both in the Health Administra?on and in the Pharmaceu?cal Industry. This is due to the professional career of Carlos Rubio Terrés, its founder, owner and director, who permeates the spirit of the company. With a profound understanding of the subtleties of the field, HEALTH VALUE, under the leadership of its Director - Carlos Rubio Terrés, is positioned to revolutionize the way healthcare solutions are conceptualized and implemented. Led by Rubio Terrés and supported by a team of experts, its mission extends beyond mere consultation; they are architects of transformation, shaping the future of healthcare delivery. pharmaceutical companies (Lederle, Wyeth, Aventis) and in HEALTH VALUE consulting. " What inspired you to establish HEALTH VALUE, and what is the company’s mission? HEALTH VALUE’s commitment to excellence, guided by Rubio Terrés’ vision, is reflected in its relentless pursuit of cutting-edge methodologies and its dedication to client success. By staying at the forefront of industry trends and regulations, they remain agile in the face of change, consistently delivering tailored solutions that drive tangible results. HEALTH VALUE’s consulting mission is to collaborate with the pharmaceutical companies from pre-launch to help define pricing and reimbursement strategies, launch and post-launch needs. In short, we help to generate the necessary evidence on the therapeutic and economic value of the new health intervention, to successfully face the introduction of the new product. We help differentiate the new drug from its competitors. Our consulting work is carried out with full involvement in the pharmaceutical company’s project and with a wide flexibility, adapting at all times to the needs of our clients. Let’s delve into the interview details and explore how HEALTH VALUE, under the leadership of Carlos Rubio Terrés, serves as a pillar of innovation and an evidence to the power of strategic thinking in the evolving healthcare sector. With a proven track record of success and a forward- thinking approach, the organization is positioned to lead the charge towards a brighter, more sustainable future for healthcare worldwide! Can you provide an overview of HEALTH VALUE’s services and the innovative solutions you offer in the healthcare sector? Can you briefly introduce yourself and your role at HEALTH VALUE? At HEALTH VALUE we work in all areas whose objective is to demonstrate the economic and clinical value of the new medicines. Of course, we carry out newly created economic analyzes (mainly probabilistic Markov models, although we work in all types of economic models) and we also adapt global economic models to the National Health System. We carry out evidence synthesis studies, through meta-analysis and systematic reviews. Finally, we present these data in Dossiers of Therapeutic and Pharmacoeconomic Value, which are very useful for pharmaceutical companies for negotiating the price and reimbursement of the new medicines with health authorities. HEALTH VALUE was born in 2003, 21 years ago, with the aim of carrying out studies and developing instruments that help define the effectiveness and efficiency of medicines and other health technologies within the scope of the Spanish National Health System. HEALTH VALUE has its roots both in the Health Administration and in the Pharmaceutical Industry. This is due to the professional career of Carlos Rubio Terrés, its founder, owner and director, who permeates the spirit of the company. Over the past four decades he has held various positions at the Pharmacobiology National Centre (Instituto de Salud Carlos III), the Spanish Ministry of Health, in a number of June 2024 www.eurohealthleaders.com 21

24. HEALTH VALUE also collaborates with pharmaceutical companies in defending the therapeutic positioning of the new drug, as well as in the review process of already marketed medications. the progress in the methodology of economic analyzes and in the applications intended to carry them out. HEALTH VALUE has accepted both challenges and has developed them with the highest standards of quality and excellence. What are your thoughts on the current state of healthcare in Spain, and how does HEALTH VALUE contribute to improving it? HEALTH VALUE plays an important role in conducting Real World Evidence studies. This is the case, for example, of the PRAXIS, ASMACOST and PREGECAM studies. HEALTH VALUE has given pharmacoeconomics courses to both the Ministry of Health and various regional governments. Although, as I indicated before, in Spain there is regulation on efficiency studies of new drugs, it is expected that these requirements will soon be developed in a new regulation. It is essential that the need for pharmacoeconomic analyzes be regulated with clarity and determination. Currently there are some sectors that view efficiency analyzes with some skepticism. All actors must be clear that these analyzes must be considered the final phase of the development of a new drug. HEALTH VALUE is open to collaborating with the Spanish health authorities to achieve these objectives. Finally and as an example, it is worth mentioning a study that we carried out on the social return on investment in relation to HIV treatments, according to which for every euro invested in antiretroviral therapy, there would be a return on investment of 6.79 Euros in Spain. To carry out this works, HEALTH VALUE has experts in health economics, meta-analysis, systematic reviews, value dossiers, research design, epidemiology, biostatistics, clinical pharmacology and clinical pharmacy. Can you share your vision for the future of HEALTH VALUE and the healthcare industry in Spain? How does HEALTH VALUE differentiate itself from other healthcare consulting firms in Spain? I began my career in Health Administration in 1979, 44 years ago. The perspective that such a long period gives makes me optimistic. Suffice it to say that a little before that date (in 1978) the first legislation on clinical trials in Spain was published. Today the evaluation of drugs meets strict criteria of scientific and methodological rigor. It is expected that in the future the systematization of drug evaluation will reach even greater heights. HEALTH VALUE is a medium-sized company that provides personalized treatment to clients and allows great flexibility in the immediate resolution of challenges that may arise in the projects. We know how the health authorities think because we were part of health authorities for 11 years. We also know what the needs of the Pharmaceutical Industry are because we were also part of it for 13 years. This ambivalence value is unique and exclusive to HEALTH VALUE in Spain. What advice would you give to aspiring entrepreneurs and leaders in the healthcare sector? I don’t think I can give advice to anyone. However, if I could give any advice, it would be to adhere to the culture of effort; because, as Lucius Anneus Seneca said 20 centuries ago “everything honest is difficult.” HEALTH VALUE has currently more than 280 publications. Over 21 years, we have carried out more than 200 economic analyses, more than 70 price and reimbursement dossiers, and dozens of systematic reviews and meta-analyses. As a trailblazer in the healthcare industry, what are some of the key challenges you have faced, and how did you overcome them? The challenges we have faced over 21 years have been mainly of two types. Firstly, the regulatory changes in Spain, which have progressively provided regulations that confirm the need for economic analyzes to justify the price and reimbursement of new medicines. And, secondly, June 2024 www.eurohealthleaders.com 22

26. E?ective Communication Strategies for Healthcare Leaders in Spain E ties and drive organizational success. As healthcare systems face mounting pressures from technological advancements, regulatory changes, and shifting patient expectations, the ability to communicate clearly, empathetically, and strategically has become more crucial than ever. ffective communication has emerged as a pivotal skill for healthcare leaders seeking to resolve industry complexi- This article explores key communication strategies that healthcare leaders in Spain can employ to enhance team engagement, improve patient care, foster transparency, and leverage technology for better outcomes. The Foundation of Organizational Success At the heart of any thriving healthcare organization lies a engaged and empowered workforce. Spanish healthcare leaders must prioritize creating an environment where every team member feels valued, heard, and motivated to contribute their best. To achieve this, leaders should: 1. Implement regular team meetings: These gatherings provide a platform for sharing updates, addressing concerns, and celebrating successes. By creating a structured yet open forum for discussion, leaders can ensure that June 2024 www.eurohealthleaders.com 24

27. all voices are heard and that the team remains aligned with organizational goals. 2. Conduct one-on-one discussions: Personal interactions allow leaders to understand individual team members' aspirations, chal- lenges, and ideas. These conversations build trust and demonstrate a leader's commitment to their staff's professional growth. 3. Establish feedback mechanisms: Implement- ing both formal and informal feedback channels encourages continuous improvement and shows that the organization values employee input. 4. Recognize and reward excellence: Publicly acknowledging outstanding performance reinforces positive behaviors and motivates others to strive for excellence. 5. Promote cross-functional collaboration: Encouraging interaction between different departments fosters innovation and helps break down silos that can hinder effective communi- cation. By consistently employing these strategies, healthcare leaders in Spain can create a culture of open communication that drives engagement, boosts morale, and ultimately leads to improved organizational performance. The Key to Better Health Outcomes Effective communication with patients and their families is not just a matter of customer service; it directly impacts health outcomes and patient satisfaction. Spanish healthcare leaders must champion communication practices that prioritize patient understanding and engage- ment. Key strategies include: 1. Training staff in active listening: Equipping healthcare professionals with active listening skills ensures that patients feel heard and understood, leading to more accurate diagnoses and treatment plans. 2. Implementing teach-back methods: This technique, where patients are asked to explain information back to the healthcare provider, helps confirm understanding and identifies areas that may need further clarification. 3. Using plain language: Encouraging the use of simple, jargon-free language helps ensure that June 2024 www.eurohealthleaders.com 25

28. Leveraging Technology for Enhanced Communication complex medical information is accessible to patients from all backgrounds. 4. Providing multilingual services: In a diverse country like Spain, offering communication support in multiple languages is crucial for ensuring equitable access to healthcare information. 5. Incorporating shared decision-making: Involving patients and families in treatment decisions fosters a sense of ownership and improves adherence to care plans. 6. Leveraging visual aids: Utilizing diagrams, models, and other visual tools can enhance understanding, particularly for complex medical concepts. In today's digital age, technology offers powerful tools for improving communication within healthcare organizations. Spanish healthcare leaders should explore and implement technological solutions that can streamline information flow, enhance collaboration, and improve patient engage- ment. Key technological strategies include: 1. Implementing secure messaging platforms: These tools allow for quick, efficient communication between healthcare providers, improving coordination of care. 2. Utilizing electronic health records (EHRs): When properly implemented, EHRs can enhance information sharing among providers and reduce errors associated with manual record-keeping. 3. Adopting telehealth solutions: Telemedicine platforms can improve access to care, particularly for patients in rural areas or those with mobility challenges. 4. Implementing patient portals: These online platforms allow patients to access their health information, communi- cate with providers, and manage appointments, promoting greater engagement in their care. 5. Using data analytics: Advanced analytics can help leaders identify communication gaps and areas for improve- ment within their organizations. 6. Exploring artificial intelligence: AI-powered chatbots and virtual assistants can provide 24/7 support for routine patient inquiries, freeing up staff for more complex interactions. By prioritizing these patient-centered communication strategies, healthcare leaders can significantly improve the quality of care provided and enhance overall patient satisfaction. Building Trust and Accountability In an era where trust in institutions is often challenged, healthcare leaders in Spain must prioritize transparency to build and maintain credibility with both staff and patients. A culture of transparency not only fosters trust but also promotes accountability and continuous improvement. To promote transparency, leaders should: 1. Regularly share organizational updates: Keeping staff informed about the organization's performance, challenges, and future plans helps create a sense of shared purpose. 2. Be open about mistakes and lessons learned: Acknowl- edging errors and discussing how to prevent them in the future demonstrates integrity and a commitment to improvement. 3. Implement open-door policies: Encouraging staff to bring concerns directly to leadership helps address issues promptly and fosters a culture of openness. 4. Publish performance metrics: Making key performance indicators publicly available demonstrates a commitment to accountability and continuous improvement. 5. Engage in community outreach: Regular communication with the broader community helps build trust and ensures that healthcare organizations remain responsive to local needs. By thoughtfully integrating these technological solutions, healthcare leaders can enhance communication efficiency, improve patient engagement, and ultimately drive better health outcomes. Conclusion Effective communication is not just a soft skill; it is a strategic imperative for healthcare leaders in Spain. By focusing on team engagement, patient-centered communi- cation, transparency, and technological innovation, leaders can navigate the complex healthcare landscape more successfully. As the industry continues to evolve, those who master these communication strategies will be best positioned to lead their organizations to success, improving both patient outcomes and organizational performance in the process. By consistently demonstrating transparency in their communications, healthcare leaders can build a foundation of trust that supports better collaboration, innovation and patient care. - Natalie May June 2024 www.eurohealthleaders.com 26

30. Innova?ve Minds in Health: Spain’s 2024 Trailblazing Leaders Dr. Mario Scheib Leading the Future of Psychiatry with Innova?ve, Intensive Therapies ental health is undergoing a transformative era, M Psychosomatic Medicine and Psychotherapy of Instituto Dr. Scheib Mallorca, Dr. Scheib’s institute offers unique and intensive treatments for mental health issues using psychedelic-assisted therapy. He combines the benefits of psychedelics, like ketamine, with advanced methods like brain stimulation and biofeedback. Dr. Scheib’s goal is to speed up recovery and make these treatments a regular part of healthcare, providing new hope for those with tough-to- treat conditions. Under his guidance, Instituto Dr. Scheib is growing globally and setting new benchmarks in mental health care. depressive mood subsided. The patient was able to reorient herself professionally and socially and showed lasting stabilization after this one intervention. This is certainly not the norm, but it motivated me to continue working in this direction. and Dr. Mario Scheib is at the lead of this transformation. As the Specialist for What is the core philosophy and approach that guides the work at your institute? Our philosophy is to help patients as quickly and as well as possible. Many people chronify while they are waiting for therapy and are treated with drugs that only help slightly better than placebo, but cause considerable, sometimes permanent side effects. And quite a few commit suicide while waiting. We therefore guarantee short-term admission in emergencies and the shortest possible treatment times, which should have as little impact as possible on social relationships. The majority of patients are able to complete therapy after two to a maximum of three weeks and only stay in contact with the therapists online if necessary. Learn more about Dr. Mario Scheib’s journey and how the institute’s innovative treatments are changing the domain of psychiatric care in our detailed interview below! Can you share your personal journey and what motivated you to establish Instituto Dr. Scheib Mallorca, specializing in psychedelic-assisted psychotherapy? How does psychedelic-assisted psychotherapy differ from traditional psychotherapy methods, and what are its potential benefits for patients? I first specialized in emergency physician and then became a specialist in psychosomatic medicine and psychotherapy. I have completed training in psychodynamics and psychoanalysis, but have also specialized in hypnotherapy, addiction medicine, biofeedback and neurofeedback. We see the use of psychedelics as a kind of turbo for psychotherapy. As the insights are faster and deeper than with traditional psychotherapy, we need significantly fewer hours of therapy. Long-established patterns of behavior can finally be changed. The majority of patients go into remission after 20 to a maximum of 30 hours. This corresponds to a treatment period of two to three weeks. This saves a lot of suffering, many costs due to inability to work and a better quality of life. I was increasingly skeptical about the traditional approach of one psychotherapy session per week. In my training courses for doctors at my institute in Mallorca, I was able to see how completely unmotivated colleagues could be motivated within a short space of time through an intensive, In 2016, I happened to hear about positive study results for the treatment of depression using ketamine. Unlike most psychiatrists, who are afraid of using anesthetics, I knew ketamine to be a safe and effective medication from my time as an emergency physician. By chance, I had just had an initial consultation with a severely depressed and suicidal patient and decided to try it out straight away. The success was extraordinary: after just one IV infusion, the suicidal thoughts had disappeared, and the June 2024 www.eurohealthleaders.com 28

31. Our philosophy is to help patients as quickly and as well as possible. Many people chronify while they are waiting for therapy and are treated with drugs that only help slightly better than placebo, but cause considerable, sometimes permanent side e?ects. And quite a few commit suicide while waiting. Dr. Mario Scheib Specialist for Psychosoma?c Medicine and Psychotherapy Ins?tuto Dr. Scheib Mallorca June 2024 www.eurohealthleaders.com 29

32. interactive training program. At that time, around the turn of the millennium, Klaus Grawe in Zurich was conducting intensive research into effective factors in psychotherapy and realized that we were probably doing the right thing, but not initially with the necessary intensity. And this is in line with the findings of psychology of learning that intensive input is needed, especially to bring about change at the beginning. sometimes permanent sexual dysfunction) with an efficacy rate just above placebo. When used properly, ketamine causes almost or no lasting side effects and has a high sustainability in combination with psychotherapy and rTMS. What are your plans for expanding access to psychedelic-assisted psychotherapy and integrating it into mainstream healthcare systems? Can you provide an overview of the specific psychedelic substances used in your treatments and the protocols followed to ensure safety and efficacy? We are currently expanding into various countries where we would like to implement the concept of a multimodal, intensive short-term therapy involving ketamine, and later other psychedelic substances, with regional partners. We are conducting scientific studies on efficiency and sustainability and hope to increasingly convince private health insurers and then also public healthcare systems of the benefits, which has already been successful with some private insurers. For legal reasons, we currently only use ketamine. We prefer racemic ketamine, which we generally use as an IV infusion. The therapist always sits next to the patient and provides reassurance. The good controllability of the infusion means that unpleasant side effects occur in less than 4% of cases. As soon as other substances are authorized, we are of course prepared to integrate them into our therapy concept. The pharmacological and legal safety of the substances and their applications is always important to us. What advice would you give to aspiring professionals or entrepreneurs interested in exploring the potential of psychedelic-assisted psychotherapy as a treatment modality? What are some of the most significant breakthroughs or advancements your institute has achieved in the field of psychedelic-assisted psychotherapy, particularly for treating psychotic disorders? Our present system of psychiatric treatment is outdated and inadequate. We work with therapy concepts that are not sustainable according to modern research findings and that cost healthcare systems a great deal of money. Current psychiatry, which works with medication that sometimes works only slightly better than a placebo and offers psychotherapeutic settings that can hardly produce any positive results simply because of their lack of intensity, has forfeited its claim to be recognized as a serious scientific discipline, and not only in my view. But there is a great deal of interest on the part of the pharmaceutical industry in retaining this method. New concepts require a rethink in many areas, but they could be worthwhile in the medium and long term. We have achieved the greatest breakthroughs in the areas of treatment-resistant depression, post-traumatic stress disorder and addiction. We also treat bipolar disorders and psychotic depression. For hallucinatory psychoses, we do not use psychedelics but transcranial magnetic stimulation, which can reduce both auditory and visual hallucinations. How do you address the ethical and legal considerations surrounding the use of psychedelics in a therapeutic setting? We carry out off-label treatment with the use of ketamine. All other therapeutic procedures are authorized in regular treatment guidelines. Off-label treatments are common in medicine: around 90% in pediatrics and 50% in oncology. Our patients are informed about this. From an ethical point of view, I personally find it problematic that therapy recommendations for the use of ketamine for depression presuppose unsuccessful treatment with at least two authorized antidepressants over a sufficiently long period of time and at a sufficiently high dose. This means accepting an unnecessary amount of suffering (weight gain and June 2024 www.eurohealthleaders.com 30

34. The Role of Innovative in Transforming Healthcare in Spain June 2024 www.eurohealthleaders.com 32

35. I n recent years, Spain has been witnessing a remarkable transformation in its healthcare system, driven by the vision and dedication of innovative leaders. These forward- thinking individuals are at the forefront of a revolution that promises to reshape the landscape of healthcare delivery, patient care, and medical research. By harnessing the power of cutting- edge technologies and fostering unprecedented collaboration between public and private sectors, these visionaries are laying the foundation for a more sustainable, patient-centric, and efficient healthcare ecosystem. Digitizing Healthcare At the heart of this transformation lies the integration of artificial intelligence (AI) and digital health solutions. Innovative leaders are spearheading initiatives that leverage these technologies to enhance patient engagement, improve clinical outcomes, and streamline healthcare processes. The development of intelligent interfaces, natural language processing (NLP) systems, and advanced user experience solutions is rapidly changing the way patients interact with healthcare providers and manage their own health. One of the most significant areas where these technologies are making an impact is in chronic disease management. Innovative leaders are working closely with healthcare professionals to implement digital health solutions that enable patients to better monitor and manage their conditions. These tools provide real- time data to both patients and their care providers, allowing for more timely interventions and personalized treatment plans. The result is not only improved patient outcomes but also a reduction in healthcare costs associated with chronic diseases. Public-private Partnership The emphasis on public-private collaboration is another crucial aspect of the ongoing healthcare transformation in Spain. Innovative leaders recognize that addressing the complex challenges of digital transformation requires a multidisciplinary approach. They are actively fostering synergies between various stakeholders, including healthcare professionals, policy makers, technology experts, and citizens. By bringing together these diverse perspectives and areas of expertise, they are able to develop innovative solutions that deliver value across the entire health ecosystem. This collaborative approach extends beyond the borders of Spain, with innovative leaders actively seeking international partnerships and knowledge exchange. They understand that global collaboration is essential for addressing shared healthcare challenges and accelerating innovation. As a result, Spain is June 2024 www.eurohealthleaders.com 33

36. increasingly becoming a hub for international healthcare innovation, attracting talent and investment from around the world. and healthcare transactions, they are enhancing data privacy, reducing administrative costs, and improving the overall efficiency of the healthcare system. Leading with Research Initiatives Challenges Research and development (R&D) is another area where innovative leaders are making significant strides. Spain has established itself as a global R&D hub for digital health solutions, with excellence centers located in key cities such as León, Madrid, Málaga, Sevilla, and Valencia. These centers are at the forefront of developing cutting-edge technologies, including advanced data management platforms, AI algorithms for diagnostics and treatment planning, and patient engagement applications. The transformation of Spain's healthcare system is not without its challenges. Innovative leaders are grappling with issues such as data privacy concerns, the need for regulatory frameworks that can keep pace with technologi- cal advancements, and the task of ensuring equitable access to digital health solutions across all segments of society. However, their commitment to addressing these challenges head-on is paving the way for sustainable solutions that will benefit generations to come. The investment in R&D is not only benefiting Spain but also contributing to the advancement of healthcare on a global scale. Innovations developed in Spanish research centers are being adopted and adapted in healthcare systems around the world, showcasing the country's growing influence in the field of digital health. As Spain continues to make strides in healthcare innova- tion, the country is positioning itself as a model for other nations seeking to modernize their healthcare systems. The visionary approach of its innovative leaders is not only improving the health outcomes of Spanish citizens but also contributing to the global advancement of healthcare technology and practices. Focus on Personalization In conclusion, the role of innovative leaders in transforming healthcare in Spain cannot be overstated. Their vision, dedication, and willingness to embrace new technologies and collaborative approaches are driving a revolution that is set to redefine the healthcare landscape. By leveraging AI, fostering public-private partnerships, investing in R&D, and addressing global healthcare challenges, these leaders are creating a more sustainable, patient-centric, and efficient healthcare ecosystem. Their efforts are empowering citizens to live longer, healthier lives and setting a new standard for healthcare innovation on the global stage. One of the key focuses of innovative leaders in Spain's healthcare sector is the development of personalized medicine. By leveraging big data analytics and AI, they are working towards tailoring treatments to individual patients based on their genetic makeup, lifestyle factors, and medical history. This approach holds the promise of more effective treatments with fewer side effects, ultimately leading to better patient outcomes and more efficient use of healthcare resources. Another area where innovative leaders are making a significant impact is in the field of telemedicine. The COVID-19 pandemic has accelerated the adoption of remote healthcare services, and Spanish healthcare leaders are seizing this opportunity to develop and implement robust telemedicine platforms. These solutions are not only improving access to healthcare services in remote areas but also reducing the burden on healthcare facilities and minimizing the risk of infection transmission. - Natalie May Innovative leaders in Spain are also focusing on improving the efficiency of healthcare administration through the implementation of blockchain technology. By creating secure, decentralized systems for managing patient records June 2024 www.eurohealthleaders.com 34

37. Stay in touch. Subscribe to Euro Health Leaders and get the magazine in print, & digital on www.eurohealthleaders.com Email: info@eurohealthleaders.com For Subscription: www.eurohealthleaders.com

38. Marta Moya Martín Co-founder & COO MIA COSMETICS PARIS

39. Innova?ve Minds in Health: Spain’s 2024 Trailblazing Leaders Marta Moya Martín Sparking a Beauty Revolu?on with Passion and Vision F founder and COO of MIA COSMETICS PARIS, Marta has leveraged her diverse background to create products that combine elegance with skin care. rom finance to fashion, and finally to the beauty and wellness industry, Marta Moya Martín’s career has been nothing short of extraordinary. As the Co- Since its launch in 2015, MIA Cosmetics Paris has become a leader in the Spanish nail polish market and is rapidly expanding internationally. Marta’s strategic vision and dedication have driven the brand to new heights, offering high-quality, affordable beauty solutions that cater to the needs of modern consumers. Let’s discover Marta Moya Martín’s inspiring journey of setting new standards in the beauty industry in the interview below! Please tell us a bit about your background and what led you to co-found MIA COSMETICS PARIS. My journey began with a degree in Business Administration from ICADE, which initially led me into the world of finance. However, I quickly realized that my true passion lay elsewhere. I transitioned into the fashion and beauty industry, gaining invaluable experience at renowned companies such as Cortefiel, Pepe Jeans, and Inditex, where I worked at Stradivarius in Barcelona. My roles in these companies, especially as the Buying Manager for outerwear at Stradivarius, honed my skills in branding, market dynamics, and leadership. The idea to co-found MIA Cosmetics Paris came from a desire to create a brand that June 2024 www.eurohealthleaders.com 37

40. Our minimalist makeup collection is formulated for a natural, everyday look, including lipsticks, CC creams, compact powders, primers, concealers, eye makeup, and more. Each product is designed to enhance natural beauty while caring for the skin. We also have our latest “Blooming Collection”, designed specifically for sensitive, reddened skin. In terms of skincare, our FLOWELL Collection aims to create moments of serenity in daily routines. Our value proposition centers on offering premium quality at affordable prices, democratizing high-end cosmetics with formulations that are accessible to all. All our products are dermatologically tested to ensure safety and suitability for every skin type. From brand imagery to product displays, everything exudes sophistication and elegance. MIA Cosmetics Paris is present in over 3,000 pharmacies in Spain and has expanded to markets in Portugal, Italy, Greece, Kuwait, Arab countries, and Slovenia. Our growth continues to exceed market averages, reflecting the marries beauty with wellness. We wanted to offer products that not only enhance appearance but also care for the skin. Inspired by the elegance of French beauty and driven by a commitment to high-quality, affordable products, we launched MIA Cosmetics Paris in 2015. Our vision was to democratize high-end cosmetics, making them accessible while maintaining premium standards. This vision, combined with a dedicated team and a focus on innovation, has allowed us to grow into a leading brand in the Spanish market and beyond. Can you give us an overview of MIA COSMETICS PARIS and the products and services you offer? MIA Cosmetics Paris, founded in 2015, is dedicated to combining the latest beauty trends with high-quality formulations under the principle of “Color & Care”. Our brand offers a wide range of products designed to bring happiness and well-being, all while maintaining a French- inspired elegance. We are the leading brand in nail polish sales in Spanish pharmacies, holding a 41% market share. Our nail polish collection features innovative 12-Free formulations, offering high pigmentation and brilliant shine, and we also provide a range of bio-sourced nail polishes made with 75% natural ingredients. Our extensive range of nail treatments includes products like the Triple 5, Bio- sourced Triple 5, SOS Magic Nails, Calcium Milk Enamel, and more. These treatments are designed to improve nail health, strengthen nails, and address specific nail concerns. June 2024 www.eurohealthleaders.com 38

41. “ How is MIA COSMETICS PARIS innovating and making a positive impact in the cosmetics industry and for your customers? We are committed to driving innovation and making a positive impact in the cosmetics industry and for our customers through several key initiatives. Firstly, we prioritize the development of high-quality, safe, and effective products. Our formulations are dermatologically tested and designed to be suitable for all skin types, ensuring that our customers can trust and rely on our products. In terms of innovation, we are constantly exploring new ingredients and technologies to enhance our product offerings. For example, our bio-sourced nail polishes utilize up to 75% natural ingredients derived from plants. This aligns with our “Color & Care” philosophy, which emphasizes both beauty and well-being. Inspired by the elegance of French beauty and driven by a commitment to high-quality, affordable products, we launched MIA Cosmetics Paris in 2015. Our vision was to democratize high-end cosmetics, making them accessible while maintaining premium standards. “ We also focus on creating products that address the real needs of our customers. Our minimalist makeup collection is designed for a natural, everyday look, catering to modern consumers who seek simplicity and efficiency in their beauty routines. By listening to our customers and understanding their preferences, we can tailor our innovations to meet their expectations and enhance their daily lives. increasing demand for our products. Through innovative marketing strategies, including educational videos, social media engagement, and collaborations with influencers and beauty boxes, we continue to build trust and awareness among consumers. Lastly, our marketing and educational efforts aim to build trust and foster a deeper connection with our audience. We use engaging content, collaborations with influencers, and transparent communication to educate our customers about our products and their benefits. This approach helps us create a loyal community that values both our brand and the positive impact we strive to make. What are you most proud of in terms of MIA COSMETICS PARIS’ accomplishments so far? I am incredibly proud of MIA Cosmetics Paris’ journey and the milestones we have achieved. One of our most significant accomplishments is becoming the number one brand in nail polish sales in Spanish pharmacies. This achievement is particularly meaningful given the competitive landscape and the initial skepticism we faced. We are proud to have secured 41% of the market share in this category, surpassing well-established competitors. Additionally, our success extends beyond nail care. We are now ranked among the top five brands in the makeup category within Spanish pharmacies. What makes these accomplishments even more gratifying is knowing that we achieved them without the extensive resources that larger companies possess. Our growth and market leadership have been driven by our commitment to high-quality products, affordability, and the principle of “Color & Care.” It is a reflection of the trust and loyalty our customers have in us, which motivates us to continue pushing the boundaries and setting new standards in the beauty industry. What advice would you give to aspiring entrepreneurs looking to start their own businesses, especially in the health and wellness space? My advice is to be authentic and true to your vision. Authenticity is key in building a brand that resonates with people. Understand what makes your brand unique and let that drive everything you do. Remember, if you are just another player in the market, you risk becoming one of the many and not standing out. Strive to be the best in your niche. This means dedicating yourself to continuous learning and improvement. Stay updated with the latest trends, research, and innovations in your field. Your commitment to excellence will set you apart and earn the trust of your customers. June 2024 www.eurohealthleaders.com 39

42. Having a clear value proposition is crucial. Know what differentiates you from your competitors and make sure this is evident in your branding, marketing, and customer interactions. Your unique selling points should be at the forefront of your communication strategy, helping you to carve out a distinct identity in a crowded market. Furthermore (and most important), be prepared to face challenges and setbacks. Entrepreneurship is a journey filled with ups and downs. Resilience and perseverance are essential traits. Learn from each experience and adapt quickly. Your ability to navigate obstacles and remain steadfast in your vision will ultimately determine your success. And finally, surround yourself with a supportive network. Build relationships with mentors, peers, and professionals who can offer guidance, feedback, and encouragement. These connections can provide invaluable insights and help you avoid common pitfalls. What’s Next for MIA COSMETICS PARIS? The future for MIA Cosme?cs Paris is incredibly exci?ng. Our primary goal is to further interna?onalize the brand and expand our presence in new markets. We are par?cularly focused on entering and establishing ourselves in the Middle Eastern markets star?ng in 2024. In the next 5-10 years, we aim to become the leading makeup brand in pharmacies, and not just in Spain. Our commitment to quality, safety, and affordability will remain at the core of our growth strategy. Overall, we envision MIA Cosme?cs Paris as a globally recognized and trusted brand, leading the market in pharmacy-based makeup and nail care. We are commi?ed to making beauty accessible and enjoyable for all, while also being a responsible and forward- thinking company. June 2024 www.eurohealthleaders.com 40

43. A Transformation in Health Care – Would The Allergy Enigma is Solved! Financial and Operating Partners for the European and North American Health Care Segment are invited. We introduce a new, revolutionary method of treating all Allergies, Asthma, Eczema, Anxiety, Stress, Phobias, and many more Life-Style Induced Ailments. We are seeking serious partners for long term investments around Europe and North America to introduce our method outside Denmark. Investment scope is +5 years with a total investment A Transformation in Health Care – Would YOU like to participate? of up to 3-4 mill. Euro. We offer education and training in English, scientific research, marketing, and license-based support for establishing a network of therapists. For more information, please write: kontakt@allergikompagniet.dk www.allergikompagniet.dk/English

44. L E A D E R S EUR Health www.eurohealthleaders.com